Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index; 12 of the 16 sources its claims cite were checked for support.
Abstract
BACKGROUND: Vaccines are needed to prevent coronavirus disease 2019 (Covid-19) and to protect persons who are at high risk for complications. The mRNA-1273 vaccine is a lipid nanoparticle-encapsulated mRNA-based vaccine that encodes the prefusion stabilized full-length spike protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes Covid-19. METHODS: This phase 3 randomized, observer-blinded, placebo-controlled trial was conducted at 99 centers across the United States. Persons at high risk for SARS-CoV-2 infection or its complications were randomly assigned in a 1:1 ratio to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo 28 days apart. The primary end point was prevention of Covid-19 illness with onset at least 14 days after the second injection in participants who had not previously been infected with SARS-CoV-2. RESULTS: The trial enrolled 30,420 volunteers who were randomly assigned in a 1:1 ratio to receive either vaccine or placebo (15,210 participants in each group). More than 96% of participants received both injections, and 2.2% had evidence (serologic, virologic, or both) of SARS-CoV-2 infection at baseline. Symptomatic Covid-19 illness was confirmed in 185 participants in the placebo group (56.5 per 1000 person-years; 95% confidence interval [CI], 48.7 to 65.3) and in 11 participants in the mRNA-1273 group (3.3 per 1000 person-years; 95% CI, 1.7 to 6.0); vaccine efficacy was 94.1% (95% CI, 89.3 to 96.8%; P<0.001). Efficacy was similar across key secondary analyses, including assessment 14 days after the first dose, analyses that included participants who had evidence of SARS-CoV-2 infection at baseline, and analyses in participants 65 years of age or older. Severe Covid-19 occurred in 30 participants, with one fatality; all 30 were in the placebo group. Moderate, transient reactogenicity after vaccination occurred more frequently in the mRNA-1273 group. Serious adverse events were rare, and the incidence was similar in the two groups. CONCLUSIONS: The mRNA-1273 vaccine showed 94.1% efficacy at preventing Covid-19 illness, including severe disease. Aside from transient local and systemic reactions, no safety concerns were identified. (Funded by the Biomedical Advanced Research and Development Authority and the National Institute of Allergy and Infectious Diseases; COVE ClinicalTrials.gov number, NCT04470427.).
Overview
CoChat Summary
TL;DR
In a phase 3 U.S. trial, mRNA-1273 (100 μg given as two doses 28 days apart) prevented symptomatic Covid-19 with 94.1% efficacy and showed no safety concerns beyond transient reactogenicity. Severe Covid-19 occurred in 30 participants, all in the placebo group.
Key findings
- Among 30,420 randomized participants (15,210 per group), the primary per-protocol analysis found symptomatic Covid-19 in 11 mRNA-1273 recipients vs. 185 placebo recipients (3.3 vs. 56.5 per 1000 person-years), for vaccine efficacy of 94.1% (95% CI, 89.3 to 96.8; P<0.001).
- Severe Covid-19 occurred in 30 participants, all in the placebo group (vaccine efficacy 100%; 95% CI could not be estimated to 1.0), including one Covid-19–related death.
- Solicited local adverse events were more frequent with mRNA-1273 after dose 1 (84.2% vs. 19.8%) and dose 2 (88.6% vs. 18.8%); solicited systemic events were also more frequent after dose 1 (54.9% vs. 42.2%) and dose 2 (79.4% vs. 36.5%). Serious adverse events were similar (0.6% in both groups).
- Efficacy was similar across subgroups, including 95.6% among participants 18 to <65 years, 86.4% among those ≥65 years, and 97.5% in communities of color.
Methods
- Phase 3 randomized, observer-blinded, placebo-controlled trial conducted at 99 U.S. centers; adults at high risk for SARS-CoV-2 infection or severe Covid-19 were assigned 1:1 to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo 28 days apart.
- The primary end point was prevention of symptomatic Covid-19 with onset at least 14 days after the second injection in per-protocol participants who were seronegative at baseline; cases were adjudicated, and vaccine efficacy was defined as 1 minus the hazard ratio (mRNA-1273 vs. placebo) using a stratified Cox proportional hazards model.
- Safety was assessed in all participants who received at least one injection, including solicited local and systemic adverse events for 7 days after each injection, unsolicited adverse events for 28 days, and serious/medically attended events through day 759.
Limitations
- Stated: short duration of safety and efficacy follow-up (median 64 days after the second dose; 2-year follow-up planned); no identified correlate of protection; insufficient data to assess asymptomatic infection; limited cases in older adults, racial/ethnic minorities, and previously infected persons; pregnant women and children were excluded.
- Stated: the trial was not designed to evaluate single-dose efficacy; rare adverse events are hard to detect given sample size; long-term risk of enhanced respiratory disease after exposure remains unknown.
- Evident: the primary analysis reflects only short-term follow-up, so durability of protection is unknown; subgroup estimates have wide confidence intervals (e.g., ≥65 years: 86.4%, 95% CI 61.4 to 95.2).
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 0 Not valid · 3 Not checked · 79 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“The efficacy of mRNA-1273 is in line with that of the recently reported BNT162b2 mRNA vaccine. 16”
What the sources say
- Supportedcites [16] 16. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 Covid-19 vaccine. N Engl J Med 2020; 383: 2603-15. source
The Abstract Results report that BNT162b2 was 95% effective in preventing Covid-19, and the Discussion likewise describes 95% efficacy after two doses. The comparison with mRNA-1273 is the citing authors’ own framing; this source supplies the BNT162b2 efficacy result. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The reactogenicity associated with immunization with mRNA-1273 in this trial is similar to that in the phase 1 data reported previously. 1,4”
What the sources say
- Supportedcites [1] 1. Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA vaccine against SARS-CoV-2 - preliminary report. N Engl J Med 2020; 383: 1920-31. source
The Methods identify this as a phase 1 trial of mRNA-1273 that evaluated reactogenicity. The Results (Vaccine Safety; page unavailable) report its reactogenicity findings, so it supports the citation’s reference to previously reported phase 1 data. (LLM, conf=0.88)
- Supportedcites [4] 4. Anderson EJ, Rouphael NG, Widge AT, et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N Engl J Med 2020; 383: 2427-38. source
The Discussion states that the authors observed no systematic differences in reactogenicity between the older participants in this study and younger mRNA-1273 recipients reported previously. It cautions that the small groups do not permit meaningful formal statistical comparisons, but the citing sentence makes only a qualitative comparison. (LLM, conf=0.93)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In the overall population, the incidence of treatment-related severe adverse events was higher in the mRNA-1273 group (71 participants [0.5%]) than in the placebo group (28 participants [0.2%]) (Tables S8 and S15).”
plainstates an associationn = 71- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Adverse events that were deemed by the trial team to be related to the vaccine or placebo were reported among 4.5% of participants in the placebo group and 8.2% in the mRNA-1273 group.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The relative incidence of these adverse events according to vaccine group was not affected by age.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
35 more claims
Create a free account to see all 88 claims and every source verdict.
- It may state two separate claims as one. 39
- Probably not a substantial claim. 21
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [44]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [31]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Currently licensed vaccines have shown efficacies of up to 95% in preventing laboratory-confirmed infection over the first few months after vaccination61–63”
From Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection (2021) · cites this paper as [62]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The two mRNA vaccines approved to date show efficacy even after only one dose, when non-NAbs and moderate T helper 1 cell responses are detectable, but almost no NAbs.”
From Immunological mechanisms of vaccine-induced protection against COVID-19 in humans (2021) · cites this paper as [82]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Robust CD4+ and CD8+ T cell memory is induced after COVID-19,22,39, 40, 41 and multiple COVID-19 vaccines elicit CD4+ and CD8+ T cell responses.26,42, 43, 44, 45”
From Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals (2021) · cites this paper as [44]
Experimental — accuracy not yet measured
43 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32661-1 · Cited by 4,616
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,406
Self-citationRNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationFolegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., Bellamy, D., Bibi, S., Bittaye, M., Clutterbuck, E. A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31604-4 · Cited by 2,419
The COVID-19 vaccine development landscape
Thanh Le, T., Andreadakis, Z., Kumar, A., Gómez Román, R., Tollefsen, S., Saville, M., & Mayhew, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/d41573-020-00073-5 · Cited by 1,954
Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis
Osterholm, M. T., Kelley, N. S., Sommer, A., & Belongia, E. A. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70295-x · Cited by 1,789
SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness
Corbett, K. S., Edwards, D. K., Leist, S. R., Abiona, O. M., Boyoglu-Barnum, S., Gillespie, R. A., Himansu, S., Schäfer, A., Ziwawo, C. T., DiPiazza, A. T., et al. (2020) · Nature · doi:10.1038/s41586-020-2622-0 · Cited by 1,615
Self-citationDeveloping Covid-19 Vaccines at Pandemic Speed
Lurie, N., Saville, M., Hatchett, R., & Halton, J. (2020) · New England Journal of Medicine · doi:10.1056/nejmp2005630 · Cited by 1,557
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
Anderson, E. J., Rouphael, N. G., Widge, A. T., Jackson, L. A., Roberts, P. C., Makhene, M., Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2028436 · Cited by 1,523
Self-citation
Cited by
Items 3,801–3,900 of 10,906
Kim, G. N., Choi, J.-A., Wu, K., Saeedian, N., Yang, E., Park, H., Woo, S., Lim, G., Kim, S.-G., Eo, S.-K., et al. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1010092 · Cited by 20
For the Passive Immunity Trial for Our Nation (PassITON) Investigators, Self, W. H., Stewart, T. G., Wheeler, A. P., Atrouni, W. E., Bistran-Hall, A. J., Casey, J. D., Cataldo, V. D., Chappell, J. D., Cohn, C. S., et al. (2021) · Trials · doi:10.1186/s13063-021-05171-2 · Cited by 19
Reporting and data sharing level for COVID-19 vaccine trials: A cross-sectional study
Duan, Y., Luo, J., Zhao, L., Zhang, X., Miao, J., Moher, D., & Bian, Z. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.103962 · Cited by 18
Webster, E. R., Peck, N. E., Echeverri, J. D., Gholizadeh, S., Tang, W.-L., Woo, R. W. L., Sharma, A., Liu, W., Rae, C. S., Sallets, A., et al. (2024) · ACS Nano · doi:10.1021/acsnano.4c05513 · Cited by 21
Lataster, R. (2024) · Journal of Evaluation in Clinical Practice · doi:10.1111/jep.13962 · Cited by 21
Ramphul, K., Ramphul, Y., Park, Y., Lohana, P. J. D., Dhillon, B. K., & Sombans, S. (2021) · Archives of Medical Science - Atherosclerotic Diseases · doi:10.5114/amsad.2021.105065 · Cited by 20
Safety survey by clinical pharmacists on COVID-19 vaccination from a single center in China
Wang, G., Zhu, L., Zhu, Y., et al. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.1913964 · Cited by 17
Ellul, P., Revés, J., Abreu, B., Chaparro, M., Gisbert, J. P., Allocca, M., Fiorino, G., Barberio, B., Zingone, F., Pisani, A., et al. (2022) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjac010 · Cited by 19
Sensitivity theorems of a model of multiple imperfect vaccines for COVID-19
Aguilar-Canto, F. J., de León, U. A.-P., & Avila-Vales, E. J. (2022) · Chaos Solitons & Fractals · doi:10.1016/j.chaos.2022.111844 · Cited by 19
Mohamed, R., White, T. M., Lazarus, J. V., Salem, A. A., Kaki, R., Marrakchi, W., Kheir, S. G. M., Amer, I. F., Ahmed, F. M., Khayat, M. A., et al. (2022) · Southern African Journal of HIV Medicine · doi:10.4102/sajhivmed.v23i1.1391 · Cited by 18
Auroux, M., Laurent, B., Coste, B., Massy, E., Mercier, A., Durieu, I., Confavreux, C. B., Lega, J., Mainbourg, S., & Coury, F. (2022) · Joint Bone Spine · doi:10.1016/j.jbspin.2022.105380 · Cited by 18
Ha, J., Park, S., Kang, H., Kyung, T., Kim, N., Kim, D., Kim, H., Bae, K., Song, M. C., Lee, K. J., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-30940-1 · Cited by 21
Niu, X., Zhang, J., Zhang, J., Bai, L., Hu, S., Zhang, Z., & Bai, M. (2024) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.4c10032 · Cited by 22
Du, H., Saiyed, S., & Gardner, L. (2024) · BMC Public Health · doi:10.1186/s12889-024-17790-w · Cited by 23
Rose, A., Nicolay, N., Martín, V. S., Mazagatos, C., Petrović, G., Baruch, J., Denayer, S., Seyler, L., Domegan, L. M., Launay, O., et al. (2023) · Eurosurveillance · doi:10.2807/1560-7917.es.2023.28.47.2300187 · Cited by 18
Nazaruk, P., Monticolo, M., Jędrzejczak, A. M., Krata, N., Moszczuk, B., Sańko-Resmer, J., Pilecki, T., Urbanowicz, A., Florczak, M., Pączek, L., et al. (2021) · Vaccines · doi:10.3390/vaccines9121454 · Cited by 18
Clinical development of cancer vaccines
Haanen, J. B. A. G., Schumacher, T. N., Kagan, J. C., Fritsch, E. F., & Wu, C. J. (2026) · Nature Medicine · doi:10.1038/s41591-026-04241-9 · Cited by 30
Autopsy findings of post-COVID-19 vaccination deaths in Tokyo Metropolis, Japan, 2021
Suzuki, H., Ro, A., Takada, A., Saito, K., & Hayashi, K. (2022) · Legal Medicine · doi:10.1016/j.legalmed.2022.102134 · Cited by 20
Sieling, P. A., King, T. B., Wong, R. M. H., Nguyen, A., Wnuk, K., Gabitzsch, E., Rice, A., Adisetiyo, H., Hermreck, M., Verma, M., et al. (2021) · medRxiv · doi:10.1101/2021.04.05.21254940 · Cited by 20
Zhou, H., Ni, W., Huang, W., Wang, Z., Cai, M., & Sun, Y.-C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.834942 · Cited by 22
Self-citationImmune Prophylaxis and Therapy for Human Cytomegalovirus Infection
Struble, E. B., Murata, H., Komatsu, T. E., & Scott, D. E. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168728 · Cited by 23
Prakash, S. (2022) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2022.102482 · Cited by 19
Schäfer, A., Kovacs, M. S., Eder, A., Nigg, A. P., & Feuchtenberger, M. (2022) · Clinical Rheumatology · doi:10.1007/s10067-022-06329-2 · Cited by 22
Anamnestic humoral correlates of immunity across SARS-CoV-2 variants of concern
McNamara, R. P., Maron, J. S., Boucau, J., Roy, V., Webb, N. E., Bertera, H. L., Barczak, A. K., Staff, T., Franko, N., Logue, J. K., et al. (2023) · mBio · doi:10.1128/mbio.00902-23 · Cited by 20
Garcia-Cirera, S., Calvet, J., Berenguer, A., Pradenas, E., Marfil, S., Massanella, M., Mateu, L., Trinité, B., Llop-Vilaltella, M., Arévalo, M., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-18996-x · Cited by 19
Zecca, E., Rizzi, M., Tonello, S., Matino, E., Costanzo, M., Rizzi, E., Casciaro, G. F., Manfredi, G. F., Acquaviva, A., Gagliardi, I., et al. (2022) · Viruses · doi:10.3390/v14081766 · Cited by 20
Tracking SARS-CoV-2 variants by entire S-gene analysis using long-range RT-PCR and Sanger sequencing
Matsubara, M., Imaizumi, Y., Fujikawa, T., Ishige, T., Nishimura, M., Miyabe, A., Murata, S., Kawasaki, K., Taniguchi, T., Igari, H., et al. (2022) · Clinica Chimica Acta · doi:10.1016/j.cca.2022.03.014 · Cited by 17
Cubic Phase‐Inducible Zwitterionic Phospholipids Improve the Functional Delivery of mRNA
Iwakawa, K., Sato, R., Konaka, M., Yamada, Y., Harashima, H., & Sato, Y. (2025) · Advanced Science · doi:10.1002/advs.202413016 · Cited by 24
mRNABERT: advancing mRNA sequence design with a universal language model and comprehensive dataset
Xiong, Y., Wang, A., Kang, Y., Shen, C., Hsieh, C., & Hou, T. (2025) · Nature Communications · doi:10.1038/s41467-025-65340-8 · Cited by 32
Operational challenges in the COVID‐19 era: Asymptomatic infections and vaccination timing
Axelrod, D. A., İnce, D., Harhay, M. N., et al. (2021) · Clinical Transplantation · doi:10.1111/ctr.14437 · Cited by 17
Schultz, M. D., Suschak, J. J., Botta, D., Silva-Sánchez, A., King, R. G., Detchemendy, T. W., Meshram, C. D., Foote, J. B., Zhou, F., Tipper, J. L., et al. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2127292 · Cited by 17
Inhibition of viral RNA-dependent RNA polymerases with clinically relevant nucleotide analogs
Maheden, K., Todd, B., Gordon, C. J., Tchesnokov, E. P., & Götte, M. (2021) · The Enzymes · doi:10.1016/bs.enz.2021.07.002 · Cited by 20
COVID-19 Vaccine Breakthrough Infections in Veterans Health AdministrationPreprint
Sharma, A., Oda, G., & Holodniy, M. (2021) · medRxiv · doi:10.1101/2021.09.23.21263864 · Cited by 20
Picazo, J. J. (2021) · Revista Española de Quimioterapia · doi:10.37201/req/085.2021 · Cited by 32
Topical TMPRSS2 inhibition prevents SARS-CoV-2 infection in differentiated human airway cultures
Guo, W., Porter, L., Crozier, T. W. M., Coates, M. L., Jha, A., McKie, M. A., Nathan, J. A., Lehner, P. J., Greenwood, E. J. D., & McCaughan, F. M. (2022) · Life Science Alliance · doi:10.26508/lsa.202101116 · Cited by 20
Cost-effectiveness of COVID-19 vaccination in low- and middle-income countries
Siedner, M., Alba, C., Fitzmaurice, K., Gilbert, R., Scott, J. A., Shebl, F. M., Ciaranello, A. L., Reddy, K. P., & Freedberg, K. (2021) · medRxiv · doi:10.1101/2021.04.28.21256237 · Cited by 18
Buckley, J. E., Landis, L. N., & Rapini, R. P. (2022) · JAAD International · doi:10.1016/j.jdin.2022.01.009 · Cited by 17
Safety Profile of COVID-19 Vaccines among Healthcare Workers in Poland
Paczkowska, A., Hoffmann, K., Michalak, M., Hans-Wytrychowska, A., Bryl, W., Kopciuch, D., Zaprutko, T., Ratajczak, P., Nowakowska, E., & Kus, K. (2022) · Vaccines · doi:10.3390/vaccines10030434 · Cited by 19
Ruiz‐Giardín, J. M., Rivilla, M., Plaza, N. M., Ortega, A. M., Rivas, L., Izquierdo-Martínez, A., Escriba, A., Martín, J. S., Bello, D. B., Madroñal, E., et al. (2022) · Viruses · doi:10.3390/v14102284 · Cited by 17
Distinct Features of Vascular Diseases in COVID-19
Ceasovschih, A., Șorodoc, V., Shor, A., Haliga, R. E., Roth, L., Lionte, C., Aursulesei, V. O., Sîrbu, O., Culiș, N., Shapieva, A. N., et al. (2023) · Journal of Inflammation Research · doi:10.2147/jir.s417691 · Cited by 18
Choi, M. J., Choi, W. S., Seong, H., et al. (2021) · Journal of Korean Medical Science · doi:10.3346/jkms.2021.36.e166 · Cited by 17
Lim, S. H., Choi, S.-H., Kim, B., Kim, J., Ji, Y.-S., Kim, S., Kim, C. K., Kim, T., Choo, E. J., Moon, J. E., et al. (2021) · Vaccines · doi:10.3390/vaccines9121379 · Cited by 16
Perioperative Coronavirus Vaccination—Timing and Implications: A Guidance Document
Merritt-Genore, H., Moosdorf, R., Gillaspie, E. A., Lother, S., Engelman, D. T., Ahmed, S., Baciewicz, F. A., Grant, M. C., Milewski, R. C. K., Cawcutt, K. A., et al. (2021) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2021.07.016 · Cited by 20
Mori, M., Yokoyama, A., Shichida, A., Sasuga, K., Maekawa, T., & Moriyama, T. (2023) · Scientific Reports · doi:10.1038/s41598-023-46823-4 · Cited by 28
Lai, C., Kim, D.-K., Kang, S., Li, K., Cha, I., Sasaki, A., Porras, J., Xia, T., & Jung, J. U. (2023) · Journal of Medical Virology · doi:10.1002/jmv.29183 · Cited by 19
Antisense oligonucleotide: A promising therapeutic option to beat COVID ‐19
Quéméner, A. M., & Galibert, M. (2021) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1703 · Cited by 20
Phase I interim results of a phase I/II study of the IgG-Fc fusion COVID-19 subunit vaccine, AKS-452
Janssen, Y. F., Feitsma, E. A., Boersma, H. H., Alleva, D. G., Lancaster, T. M., Sathiyaseelan, T., Murikipudi, S., Delpero, A. R., Scully, M. M., Ragupathy, R., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.01.043 · Cited by 16
Ramsay Hunt syndrome following COVID-19 vaccination
Woo, C. J., Chou, O. H. I., & Cheung, B. M. Y. (2022) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2021-141022 · Cited by 17
Cancer or COVID-19? A Review of Recommendations for COVID-19 Vaccination in Cancer Patients
Gundavda, M. K., & Gundavda, K. K. (2021) · Current Treatment Options in Oncology · doi:10.1007/s11864-021-00903-7 · Cited by 16
Bouwmans, P., Messchendorp, A. L., Imhof, C., Sanders, J., Hilbrands, L. B., Reinders, M. E. J., Vart, P., Bemelman, F. J., Abrahams, A. C., van den Dorpel, R. M. A., et al. (2022) · Clinical Kidney Journal · doi:10.1093/ckj/sfac249 · Cited by 20
Durojaye, O. A., Sedzro, D. M., Idris, M. O., Yekeen, A. A., Fadahunsi, A. A., & Alakanse, O. S. (2022) · ChemistrySelect · doi:10.1002/slct.202103903 · Cited by 17
Establishing long-lasting vaccine immunity: insights from mRNA and adjuvanted protein platforms
Pineda-Peña, A.-C., Hasegawa, K., Pavot, V., Berry, C., Combadière, B., Cortés-Garcia, G., McDermott, A. B., & Sridhar, S. (2025) · npj Vaccines · doi:10.1038/s41541-025-01302-x · Cited by 25
Badanta, B., García, M. A., Jiménez, Á. E., Lucchetti, G., & de Diego‐Cordero, R. (2023) · EXPLORE · doi:10.1016/j.explore.2023.02.005 · Cited by 19
A Route to Synthesize Ionizable Lipid ALC-0315, a Key Component of the mRNA Vaccine Lipid Matrix
Boldyrev, I. A., Shendrikov, V. P., Vostrova, A. G., & Vodovozova, E. L. (2023) · Russian Journal of Bioorganic Chemistry · doi:10.1134/s1068162023020061 · Cited by 19
Feuchtenberger, M., Kovacs, M. S., Eder, A., Nigg, A. P., & Schäfer, A. (2022) · Rheumatology International · doi:10.1007/s00296-022-05123-2 · Cited by 20
Zou, Z., Fairley, C. K., Shen, M., Scott, N., Xu, X., Li, Z., Li, R., Zhuang, G., & Zhang, L. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.11.024 · Cited by 18
Non-Viral RNA Therapies for Non-Small Cell Lung Cancer and Their Corresponding Clinical Trials
Tiwade, P. B., Fung, V., VanKeulen‐Miller, R., Narasipura, E. A., Ma, Y., & Fenton, O. S. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c00871 · Cited by 21
Implication of the emergence of the delta (B.1.617.2) variants on vaccine effectiveness
Al‐Tawfiq, J. A., Koritala, T., Alhumaid, S., Barry, M. A., Alshukairi, A. N., Temsah, M.-H. A., Mutair, A. S. A., Rabaan, A. A., Tirupathi, R., & Gautret, P. (2022) · Infection · doi:10.1007/s15010-022-01759-1 · Cited by 17
Salmanton‐García, J., Marchesi, F., Koehler, P. A., Weinbergerová, B., Čolović, N., Falces‐Romero, I., Buquicchio, C., Farina, F., Praet, J. T. V., Biernat, M., et al. (2023) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2023.106952 · Cited by 17
IL-7 promotes mRNA vaccine-induced long-term immunity
Wang, L., Wan, J., He, W., Wang, Z., Wu, Q. D., Zhou, M., Fu, Z. F., & Zhao, L. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02993-5 · Cited by 18
Mitchell, J., Connolly, C. M., Chiang, T. P., Alejo, J. L., Werbel, W. A., Segev, D. L., & Massie, A. B. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.11897 · Cited by 15
Kode, J., Maharana, J., Dar, A. A., Mukherjee, S., Gadewal, N., Sigalapalli, D. K., Kumar, S., Panda, D., Ghosh, S., Keshry, S. S., et al. (2023) · ACS Omega · doi:10.1021/acsomega.2c07138 · Cited by 18
An mpox quadrivalent mRNA vaccine protects mice from lethal vaccinia virus challenge
Li, E., Gong, Q., Zhang, J., Guo, X., Xie, W., Chen, D., Shen, Y., Hong, D., Li, Z., Wang, Q., et al. (2024) · Antiviral Research · doi:10.1016/j.antiviral.2024.105974 · Cited by 21
Uncertainty analysis of facemasks in mitigating SARS-CoV-2 transmission
Liu, F., & Qian, H. (2022) · Environmental Pollution · doi:10.1016/j.envpol.2022.119167 · Cited by 18
Mack, P. C., Gomez, J. E., Rodilla, A. M., Carreño, J. M., Hsu, C., Rolfo, C., Meshulami, N., Moore, A. C., Brody, R., King, J. C., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.04.012 · Cited by 18
The importance of sustained compliance with physical distancing during COVID-19 vaccination rollout
Teslya, A., Rozhnova, G., Pham, T. M., van Wees, D. A., Nunner, H., Godijk, N. G., Bootsma, M., & Kretzschmar, M. (2022) · Communications Medicine · doi:10.1038/s43856-022-00207-3 · Cited by 17
ter Huurne, M., Parker, B. L., Liu, N. Q., Qian, E. L., Vivien, C. J., Karavendzas, K., Mills, R. J., Saville, J. T., Abu-Bonsrah, K. D., Wise, A. F., et al. (2023) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2023.07.013 · Cited by 18
Fidler, S. J., Fox, J. M., Tipoe, T., Longet, S., Tipton, T., Abeywickrema, M., Adele, S., Alagaratnam, J., Ali, M., Aley, P. K., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac796 · Cited by 21
Marco, G. D., Giryes, S., Williams, K., Alcorn, N., Slade, M., Fitton, J. M., Nizam, S., Smithson, G., Iqbal, K., Tran, G. T., et al. (2022) · Vaccines · doi:10.3390/vaccines10081184 · Cited by 17
Wang, X., Pahwa, A., Bausch-Jurken, M. T., Chitkara, A., Sharma, P., Malmenäs, M., Vats, S., Whitfield, M. G., Lai, K. Z. H., Dasari, P., et al. (2025) · Advances in Therapy · doi:10.1007/s12325-025-03117-7 · Cited by 18
“…safety of the two mRNA vaccines developed against the ancestral SARS‑ CoV‑2 strain, mRNA‑1273 (Spikevax®; Moderna, Inc., Cambridge, MA, USA) [6] and BNT162b2 (Comirnaty®; Pfizer/BioNTech, New York, NY, USA/Mainz, Germany) [7], were demonstrated in phase 3 randomized controlled trials (RCTs) [8, 9].”
Durability of immune responses to the BNT162b2 mRNA vaccine
(2021) · doi:10.1101/2021.09.30.462488 · Cited by 17
Chi, G., Montazerin, S. M., Lee, J., Kazmi, S. H. A., Shojaei, F., Fitzgerald, C., & Gibson, C. M. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27259 · Cited by 17
A framework for monitoring population immunity to SARS-CoV-2
Lopman, B. A., Shioda, K., Nguyen, Q., Beckett, S. J., Siegler, A. J., Sullivan, P. S., & Weitz, J. S. (2021) · Annals of Epidemiology · doi:10.1016/j.annepidem.2021.08.013 · Cited by 17
SARS-CoV-2: The Interplay Between Evolution and Host Immunity
Case, J. B., Jain, S., Suthar, M. S., & Diamond, M. (2024) · Annual Review of Immunology · doi:10.1146/annurev-immunol-083122-043054 · Cited by 29
“First-generation SARS-CoV-2 vaccines utilizing the Wuhan-1 spike sequence such as mRNA-1273 were 94% and 100% effective against infection and severe disease (178), respectively.”
Kiem, C. T., Andronico, A., Bosetti, P., Paireau, J., Alter, L., Boëlle, P., Fontanet, A. L., Lévy-Bruhl, D., & Cauchemez, S. (2021) · Eurosurveillance · doi:10.2807/1560-7917.es.2021.26.26.2100533 · Cited by 17
SARS-CoV-2: Outline, Prevention, and Decontamination
Janik, E., Bartos, M., Niemcewicz, M., Gorniak, L., & Bijak, M. (2021) · Pathogens · doi:10.3390/pathogens10020114 · Cited by 22
Long Term Immune Response Produced by the SputnikV Vaccine
Martynova, E. V., Hamza, S., Garanina, E. E., Kabwe, E., Markelova, M., Shakirova, V. G., Хаертынова, И. М., Kaushal, N., Baranwal, M., Rizvanov, A. A., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222011211 · Cited by 19
Godbout, A., Drolet, M., Mondor, M., Simard, M., Sauvageau, C., Serres, G. D., & Brisson, M. (2022) · BMC Medicine · doi:10.1186/s12916-022-02398-x · Cited by 18
COVID-19 vaccines and vaccine administration
Gordon, C., Porteous, D., & Unsworth, J. (2021) · British Journal of Nursing · doi:10.12968/bjon.2021.30.6.344 · Cited by 15
SARS-CoV-2 Reinfections: Overview of Efficacy and Duration of Natural and Hybrid ImmunityPreprint
Pilz, S., Theiler‐Schwetz, V., Trummer, C., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4005459 · Cited by 17
Brown, C. M., Morlock, A., Blakolmer, K., Heidari, E., & Morlock, R. (2022) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2022.28.12.1429 · Cited by 19
Hein, S., Mhedhbi, I., Zahn, T. R., Sabino, C., Benz, N. I., Husria, Y., Renelt, P. M., Braun, F., Oberle, D., Maier, T. J., et al. (2022) · Vaccines · doi:10.3390/vaccines10050796 · Cited by 17
Reinfection of SARS-CoV-2 – analysis of 23 cases from the literature
Roberts, A. T., Piani, F., Longo, B., Andreini, R., & Meini, S. (2021) · Scandinavian Journal of Infectious Diseases · doi:10.1080/23744235.2021.1905174 · Cited by 17
Nanoparticle- and Microparticle-Based Vaccines against Orbiviruses of Veterinary Importance
Jiménez-Cabello, L., Utrilla-Trigo, S., Barreiro-Piñeiro, N., Pose‐Boirazian, T., Martínez-Costas, J., Marín-López, A., & Ortego, J. (2022) · Vaccines · doi:10.3390/vaccines10071124 · Cited by 19
Cohen, D. A., Greenberg, P., Formanowski, B., & Parikh, P. D. (2022) · Medicine · doi:10.1097/md.0000000000028839 · Cited by 19
DNA-terminus-dependent transcription by T7 RNA polymerase and its C-helix mutants
Yu, B., Chen, Y., Yan, Y., Lu, X., & Zhu, B. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkae593 · Cited by 21
Xiangxun, C., Wu, Y., Dau, V. T., Nguyen, N., & Ta, H. T. (2023) · Biomaterials Science · doi:10.1039/d2bm01594c · Cited by 21
Optimal Social Distancing Policy for COVID-19 Control in Korea: A Model-Based Analysis
Jo, Y., Shrestha, S., Radnaabaatar, M., Park, H., & Jung, J. (2022) · Journal of Korean Medical Science · doi:10.3346/jkms.2022.37.e189 · Cited by 20
New-Onset and Relapsed Membranous Nephropathy post SARS-CoV-2 and COVID-19 Vaccination
Ma, Q., Li, X., & Xu, G. (2022) · Viruses · doi:10.3390/v14102143 · Cited by 18
Emerging heterologous mRNA-based booster strategies within the COVID-19 vaccine landscape
Das, R., Hyer, R. N., Burton, P. B. J., Miller, J. M., & Kuter, B. J. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2153532 · Cited by 20
Self-citationHarboe, Z. B., Hamm, S. R., Pérez‐Alós, L., Sivapalan, P., Priemé, H., Wilcke, T., Kjeldgaard, P., Shaker, S. B., Jordan, A. S., Møller, D. L., et al. (2022) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2022-001268 · Cited by 20
Novel mRNA vaccines induce potent immunogenicity and afford protection against tuberculosis
Voss, C. J. D., Marcellus, Li, S., Ateere, A., McShane, H., & Stylianou, E. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1540359 · Cited by 30
Murano, K., Guo, Y., & Siomi, H. (2021) · Biochemical Society Transactions · doi:10.1042/bst20210859 · Cited by 19
Park, S., & Suh, Y. (2023) · Journal of Medical Internet Research · doi:10.2196/42623 · Cited by 16
Tang, H., Gao, L., Wu, Z., Meng, F., Zhao, X., Shao, Y., Hou, G., Du, X., & Qin, F. X.-F. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.836232 · Cited by 17
Smith, L., Sim, J., Amlôt, R., Cutts, M., Dasch, H. K., Sevdalis, N., Rubin, G. J., & Sherman, S. M. (2021) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2021.110679 · Cited by 17
The significance of advanced COVID-19 diagnostic testing in pandemic control measures
Kwok, H. F. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.72837 · Cited by 22
Metadata
- Authors
- Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., McGettigan, J., Khetan, S., Segall, N., Solis, J., Brosz, A., Fierro, C., Schwartz, H., Neuzil, K., Corey, L., Gilbert, P., Janes, H., Follmann, D., Marovich, M., Mascola, J., Polakowski, L., Ledgerwood, J., Graham, B. S., Bennett, H., Pajon, R., Knightly, C., Leav, B., Deng, W., Zhou, H., Han, S., Ivarsson, M., Miller, J., & Zaks, T.
- Affiliations
- Brigham and Women's Hospital (US)
- From Brigham and Women’s Hospital (L.R.B.), Boston, and Moderna, Cambridge (H.B., R.P., C.K., B.L., W.D., H.Z., S.H., M.I., J. Miller, T.Z.) — both in Massachusetts; Baylor College of Medicine (H.M.E.S.) and Centex Studies (J.S.) — both in Houston; Meridian Clinical Research, Savannah (B.E., S.K., A.B.), and Emory University (N.R.) and Atlanta Clinical Research Center (N.S.), Atlanta — all in Georgia; University of Maryland School of Medicine, Baltimore (K.K., K.N.), and National Institute of Allergy and Infectious Diseases, Bethesda (D.F., M.M., J. Mascola, L.P., J.L., B.S.G.) — both in Maryland; Saint Louis University School of Medicine, St. Louis (S.F.); University of Illinois, Chicago, Chicago (R.N.); George Washington University School of Medicine and Health Sciences, Washington, DC (D.D.); University of California, San Diego, San Diego (S.A.S.); Vanderbilt University School of Medicine, Nashville (C.B.C.); Quality of Life Medical and Research Center, Tucson, AZ (J. McGettigan); Johnson County Clin-Tr...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-02-04
- Volume
- 384
- Issue
- 5
- Pages
- 403-416
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7787219
- OpenAlex
- W3113734454
- Cited by
- 10,119
- References
- 24
- Citations by year
- 2026: 622 · 2025: 962 · 2024: 1186 · 2023: 1691 · 2022: 2854 · 2021: 2793
- FWCI
- 240.84
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- New England Journal of Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (ACTG Leadership and Operations Center UM1 AI 68636, HPTN Leadership and Operations Center UM1 AI 68619, HVTN Laboratory Center UM1 AI 68618, HVTN Leadership and Operations Center UM1 AI 68614, HVTN Statistics and Data Management Center UM1 AI, IDCRC leadership group 5 UM1 AI148684-03)
- Federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority (Contract No. 75A50120C00034)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- mRNA-1273 vaccine, SARS-CoV-2, COVID-19 vaccines, vaccine efficacy, vaccine safety, reactogenicity, adverse events, vulnerable populations, older adults, immunocompromised patients, breakthrough infection, severe COVID-19 prevention
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, 2019-nCoV Vaccine mRNA-1273, Adolescent, Adult, Aged, Female, Humans, Male, Middle Aged, Incidence, Single-Blind Method, Treatment Outcome, Young Adult, Patient Acuity, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.